Fintel reports that on May 27, 2026, JP Morgan initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a Overweight recommendation.
Analyst Price Forecast Suggests 376.85% Upside
As of May 14, 2026, the average one-year price target for Larimar Therapeutics is $16.55/share. The forecasts range from a low of $7.07 to a high of $27.30. The average price target represents an increase of 376.85% from its latest reported closing price of $3.47 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Larimar Therapeutics is 0MM. The projected annual non-GAAP EPS is -1.75.
What is the Fund Sentiment?
There are 169 funds or institutions reporting positions in Larimar Therapeutics. This is an decrease of 29 owner(s) or 14.65% in the last quarter. Average portfolio weight of all funds dedicated to LRMR is 0.07%, an increase of 6.93%. Total shares owned by institutions increased in the last three months by 12.78% to 84,491K shares. 
The put/call ratio of LRMR is 0.22, indicating a bullish outlook.
What are Other Shareholders Doing?
Deerfield Management Company, L.p. holds 35,607K shares representing 34.28% ownership of the company. In its prior filing, the firm reported owning 30,607K shares , representing an increase of 14.04%. The firm increased its portfolio allocation in LRMR by 26.93% over the last quarter.
Millennium Management holds 3,625K shares representing 3.49% ownership of the company. In its prior filing, the firm reported owning 5,206K shares , representing a decrease of 43.61%. The firm decreased its portfolio allocation in LRMR by 18.61% over the last quarter.
AIGH Capital Management holds 3,000K shares representing 2.89% ownership of the company. In its prior filing, the firm reported owning 2,000K shares , representing an increase of 33.33%. The firm decreased its portfolio allocation in LRMR by 0.17% over the last quarter.
Driehaus Capital Management holds 2,934K shares representing 2.82% ownership of the company. In its prior filing, the firm reported owning 535K shares , representing an increase of 81.75%. The firm increased its portfolio allocation in LRMR by 598.05% over the last quarter.
Vanguard Capital Management holds 2,866K shares representing 2.76% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
